\-\ Texto\\:\\ \ \(0\)\
\-\ diffuse\\ abdominal\\ tenderness\\,\\ distention\\.\ \(0\)\
\-\ non\\-acute\\ abdomen\\ with\\ no\\ rebound\\.\ \(0\)\
\-\ temp\\:\\ 99\\.1f\ \(0\)\
\-\ wbc\\:\\ 10\\.1\ \(0\)\
\-\ chloride\\ high\\ at\\ 115\ \(0\)\
\-\ potassium\\ low\\ at\\ 3\\.5\ \(0\)\
\-\ metronidazole\\ or\\ vancomycin\\ for\\ 7\\-10\\ days\\.\ \(0\)\
\-\ limited\\ plain\\ film\\ of\\ the\\ upright\\ abdomen\\ shows\\ thickened\\ haustra\\ of\\ the\\ transverse\\ colon\\.\ \(0\)\
\-\ selected\\ axial\\,\\ oral\\ and\\ iv\\ contrast\\ enhanced\\,\\ images\\ show\\ substantially\\ thickened\\ colonic\\ bowel\\ wall\\ with\\ preservation\\ of\\,\\ but\\ thickened\\,\\ haustra\\,\\ comprising\\ the\\ entire\\ colon\\.\\ \\ small\\ bowel\\ is\\ not\\ affected\\.\\ mild\\ pericolonic\\ fat\\ stranding\\ is\\ present\\.\ \(0\)\
\-\ pseudomembranous\\ colitis\ \(3\)\
\-\ inflammatory\\ bowel\\ disease\\ \ \(9\)\
\-\ infectious\\ colitis\\ \\(c\\.\\ difficile\\,\\ yersinia\\,\\ shigella\\,\\ cmv\\)\ \(0\)\
\-\ ischemia\ \(171\)\
\-\ lymphoma\ \(373\)\
\-\ 78yo\\ male\\ presents\\ to\\ ed\\ with\\ a\\ three\\ week\\ history\\ of\\ persistent\\ diarrhea\\ and\\ new\\ onset\\ of\\ diffuse\\ abdominal\\ pain\\ and\\ distension\\.\\ \\ the\\ patient\\ was\\ seen\\ one\\ month\\ ago\\ by\\ his\\ primary\\ care\\ provider\\ and\\ treated\\ for\\ sinusitis\\.\ \(0\)\
\-\ pseudomembranous\\ colitis\\ is\\ a\\ toxin\\ induced\\ inflammatory\\ infection\\ of\\ the\\ colon\\ caused\\ overgrowth\\ of\\ clostridium\\ difficile\\,\\ secondary\\ to\\ antibiotic\\ use\\.\\ \\ historically\\ associated\\ with\\ clindamycin\\,\\ this\\ entity\\ can\\ occur\\ subsequent\\ to\\ almost\\ any\\ antibiotic\\,\\ as\\ well\\ as\\,\\ steroids\\ and\\ chemotherapeutic\\ drugs\\.\\ symptoms\\ begin\\ as\\ early\\ as\\ one\\ day\\ after\\ starting\\ the\\ medication\\ and\\ as\\ late\\ as\\ six\\ weeks\\ after\\ cessation\\.\\ \\ common\\ presentations\\ include\\ low\\ fevers\\,\\ leukocytosis\\,\\ diffuse\\ abdominal\\ pain\\,\\ and\\ of\\ course\\ diarrhea\\.\\ \\ the\\ diarrhea\\ is\\ typically\\ non\\-bloody\\ and\\ should\\ not\\ contain\\ mucous\\.\\ \\ diagnosis\\ is\\ made\\ with\\ fecal\\ testing\\ for\\ toxin\\ by\\ elisa\\ and\\ latex\\ agglutination\\ for\\ c\\.\\ difficile\\.\\ \\ \ \(0\)\
\-\ abnormal\\ plain\\ film\\ findings\\ are\\ seen\\ in\\ 40\\%\\ of\\ patients\\ and\\ include\\ thumbprinting\\,\\ ileus\\,\\ thickened\\ haustra\\,\\ and\\ megacolon\\.\ \(0\)\
\-\ ct\\ findings\\ show\\ a\\ substantially\\ thickened\\ \\(typically\\ \\>15mm\\)\\ colonic\\ wall\\ with\\ preserved\\ haustra\\.\\ findings\\ occur\\ first\\ distally\\ in\\ the\\ rectum\\ and\\ then\\ progress\\ proximally\\.\\ \\ contrast\\ between\\ thickened\\ haustra\\ is\\ described\\ as\\ the\\ accordion\\ sign\\,\\ but\\ is\\ not\\ specific\\.\\ \\ the\\ terminal\\ ileum\\ is\\ typically\\ not\\ affected\\.\\ \\ ascites\\ and\\ pericolonic\\ fat\\ stranding\\ are\\ associated\\ with\\ this\\ disease\\ process\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ haustra\\:\\ 0\\.11055739448851559\ \(0\)\
\-\ thickened\\:\\ 0\\.0658781398669025\ \(0\)\
\-\ difficile\\:\\ 0\\.056890778051263136\ \(0\)\
\-\ colitis\\:\\ 0\\.040301295463507796\ \(0\)\
\-\ substantially\\:\\ 0\\.039367382664247476\ \(0\)\
\-\ diarrhea\\:\\ 0\\.03811024460709985\ \(0\)\
\-\ toxin\\:\\ 0\\.037927185367508755\ \(0\)\
\-\ pericolonic\\:\\ 0\\.035819880037277714\ \(0\)\
\-\ pseudomembranous\\:\\ 0\\.035819880037277714\ \(0\)\
\-\ colon\\:\\ 0\\.02884756082941839\ \(0\)\
\-\ c\\.\\:\\ 0\\.028334197209504915\ \(0\)\
\-\ colonic\\:\\ 0\\.026685589344451723\ \(0\)\
\-\ typically\\:\\ 0\\.025929161342458214\ \(0\)\
\-\ as\\:\\ 0\\.025925623327389385\ \(0\)\
\-\ non\\-acute\\:\\ 0\\.025259365111651857\ \(0\)\
\-\ 99\\.1f\\:\\ 0\\.025259365111651857\ \(0\)\
\-\ 78yo\\:\\ 0\\.025259365111651857\ \(0\)\
\-\ agglutination\\:\\ 0\\.025259365111651857\ \(0\)\
\-\ antibiotic\\:\\ 0\\.025059410701869234\ \(0\)\
\-\ stranding\\:\\ 0\\.02368703264666062\ \(0\)\
\-\ elisa\\:\\ 0\\.02327327003841419\ \(0\)\
\-\ latex\\:\\ 0\\.02327327003841419\ \(0\)\
\-\ bowel\\:\\ 0\\.023036849852877586\ \(0\)\
\-\ diffuse\\:\\ 0\\.02223788613503136\ \(0\)\
\-\ 10\\.1\\:\\ 0\\.022111478897703117\ \(0\)\
\-\ non\\-bloody\\:\\ 0\\.022111478897703117\ \(0\)\
\-\ thumbprinting\\:\\ 0\\.022111478897703117\ \(0\)\
\-\ accordion\\:\\ 0\\.022111478897703117\ \(0\)\
\-\ chemotherapeutic\\:\\ 0\\.021287174965176524\ \(0\)\
\-\ affected\\:\\ 0\\.02118925278825068\ \(0\)\
\-\ shigella\\:\\ 0\\.02012538382446545\ \(0\)\
\-\ clostridium\\:\\ 0\\.02012538382446545\ \(0\)\
\-\ historically\\:\\ 0\\.02012538382446545\ \(0\)\
\-\ megacolon\\:\\ 0\\.02012538382446545\ \(0\)\
\-\ clindamycin\\:\\ 0\\.019683691332123738\ \(0\)\
\-\ 15mm\\:\\ 0\\.019683691332123738\ \(0\)\
\-\ overgrowth\\:\\ 0\\.01930107989193886\ \(0\)\
\-\ 115\\:\\ 0\\.018963592683754377\ \(0\)\
\-\ 7\\-10\\:\\ 0\\.018963592683754377\ \(0\)\
\-\ yersinia\\:\\ 0\\.018963592683754377\ \(0\)\
\-\ film\\:\\ 0\\.018808761806527095\ \(0\)\
\-\ comprising\\:\\ 0\\.01866170008874628\ \(0\)\
\-\ occur\\:\\ 0\\.018372760050324004\ \(0\)\
\-\ abdominal\\:\\ 0\\.018360337290447983\ \(0\)\
\-\ metronidazole\\:\\ 0\\.018139288751227785\ \(0\)\
\-\ presentations\\:\\ 0\\.018139288751227785\ \(0\)\
\-\ chloride\\:\\ 0\\.017909940018638857\ \(0\)\
\-\ fecal\\:\\ 0\\.017499908948035207\ \(0\)\
\-\ potassium\\:\\ 0\\.017141275300602526\ \(0\)\
\-\ inflammatory\\:\\ 0\\.01698175326184541\ \(0\)\
\-\ vancomycin\\:\\ 0\\.016822577205730826\ \(0\)\
\-\ begin\\:\\ 0\\.016275140997241686\ \(0\)\
\-\ plain\\:\\ 0\\.01590409004406352\ \(0\)\
\-\ cmv\\:\\ 0\\.015711501185648406\ \(0\)\
\-\ proximally\\:\\ 0\\.015711501185648406\ \(0\)\
\-\ findings\\:\\ 0\\.015634701453781888\ \(0\)\
\-\ starting\\:\\ 0\\.015610952991346773\ \(0\)\
\-\ \\,\\:\\ 0\\.015513470803282945\ \(0\)\
\-\ upright\\:\\ 0\\.015419860227740263\ \(0\)\
\-\ cessation\\:\\ 0\\.015419860227740263\ \(0\)\
\-\ preservation\\:\\ 0\\.015072121382455828\ \(0\)\
\-\ provider\\:\\ 0\\.015072121382455828\ \(0\)\
\-\ leukocytosis\\:\\ 0\\.015072121382455828\ \(0\)\
\-\ ileus\\:\\ 0\\.015072121382455828\ \(0\)\
\-\ show\\:\\ 0\\.015032412232043702\ \(0\)\
\-\ entity\\:\\ 0\\.01499140253727905\ \(0\)\
\-\ fat\\:\\ 0\\.0148934803603532\ \(0\)\
\-\ selected\\:\\ 0\\.014836482132493159\ \(0\)\
\-\ induced\\:\\ 0\\.01468950994227095\ \(0\)\
\-\ abdomen\\:\\ 0\\.014506500073900839\ \(0\)\
\-\ preserved\\:\\ 0\\.01448228741625483\ \(0\)\
\-\ distally\\:\\ 0\\.014352022734086471\ \(0\)\
\-\ 3\\.5\\:\\ 0\\.014289045924004021\ \(0\)\
\-\ distension\\:\\ 0\\.01422742355947404\ \(0\)\
\-\ wall\\:\\ 0\\.01418429295265757\ \(0\)\
\-\ sinusitis\\:\\ 0\\.014167098604752458\ \(0\)\
\-\ not\\:\\ 0\\.014152649532858858\ \(0\)\
\-\ mucous\\:\\ 0\\.014108017552595619\ \(0\)\
\-\ terminal\\:\\ 0\\.014050130139078371\ \(0\)\
\-\ ascites\\:\\ 0\\.014050130139078371\ \(0\)\
\-\ progress\\:\\ 0\\.013829611396567977\ \(0\)\
\-\ include\\:\\ 0\\.013737269272379867\ \(0\)\
\-\ ileum\\:\\ 0\\.013725406112410741\ \(0\)\
\-\ rectum\\:\\ 0\\.013674690991782085\ \(0\)\
\-\ low\\:\\ 0\\.013617008898947848\ \(0\)\
\-\ temp\\:\\ 0\\.013575876733698505\ \(0\)\
\-\ drugs\\:\\ 0\\.013527718801559879\ \(0\)\
\-\ contain\\:\\ 0\\.013527718801559879\ \(0\)\
\-\ one\\:\\ 0\\.013270666953069594\ \(0\)\
\-\ distention\\:\\ 0\\.013086026309218162\ \(0\)\
\-\ is\\:\\ 0\\.012889186897071074\ \(0\)\
\-\ rebound\\:\\ 0\\.012812931238145598\ \(0\)\
\-\ late\\:\\ 0\\.012739457224926868\ \(0\)\
\-\ medication\\:\\ 0\\.01233426623911074\ \(0\)\
\-\ entire\\:\\ 0\\.012035524089184065\ \(0\)\
\-\ six\\:\\ 0\\.012035524089184065\ \(0\)\
\-\ almost\\:\\ 0\\.01184351632333031\ \(0\)\
\-\ testing\\:\\ 0\\.01184351632333031\ \(0\)\
\-\ fevers\\:\\ 0\\.011638762844871444\ \(0\)\
\-\ associated\\:\\ 0\\.011555659380559895\ \(0\)\
\-\ steroids\\:\\ 0\\.011517844923695578\ \(0\)\
\-\ ischemia\\:\\ 0\\.01137917288684214\ \(0\)\
\-\ contrast\\:\\ 0\\.010961465253913498\ \(0\)\
\-\ infectious\\:\\ 0\\.010526804777833347\ \(0\)\
\-\ enhanced\\:\\ 0\\.01047697170416037\ \(0\)\
\-\ but\\:\\ 0\\.010444144991596203\ \(0\)\
\-\ described\\:\\ 0\\.010427990519749767\ \(0\)\
\-\ ed\\:\\ 0\\.010348171165873074\ \(0\)\
\-\ limited\\:\\ 0\\.0103324706909028\ \(0\)\
\-\ oral\\:\\ 0\\.010316855777528689\ \(0\)\
\-\ 40\\:\\ 0\\.010301325498246914\ \(0\)\
\-\ caused\\:\\ 0\\.010270515206624389\ \(0\)\
\-\ after\\:\\ 0\\.010131812049336403\ \(0\)\
\-\ specific\\:\\ 0\\.010121245545067364\ \(0\)\
\-\ transverse\\:\\ 0\\.00981789883710601\ \(0\)\
\-\ persistent\\:\\ 0\\.00976603625359994\ \(0\)\
\-\ made\\:\\ 0\\.00975321596593541\ \(0\)\
\-\ use\\:\\ 0\\.009677475974336111\ \(0\)\
\-\ seen\\:\\ 0\\.009676949083482465\ \(0\)\
\-\ subsequent\\:\\ 0\\.009531749850457913\ \(0\)\
\-\ process\\:\\ 0\\.009427121733050757\ \(0\)\
\-\ course\\:\\ 0\\.009239345110188084\ \(0\)\
\-\ ago\\:\\ 0\\.009113836162742833\ \(0\)\
\-\ early\\:\\ 0\\.008954610228201827\ \(0\)\
\-\ iv\\:\\ 0\\.008935315007051844\ \(0\)\
\-\ wbc\\:\\ 0\\.008925715904228687\ \(0\)\
\-\ care\\:\\ 0\\.008831453143463473\ \(0\)\
\-\ then\\:\\ 0\\.008713372144475902\ \(0\)\
\-\ new\\:\\ 0\\.008532343773067502\ \(0\)\
\-\ sign\\:\\ 0\\.00848265473284834\ \(0\)\
\-\ for\\:\\ 0\\.008356540385589858\ \(0\)\
\-\ week\\:\\ 0\\.00831523042500925\ \(0\)\
\-\ three\\:\\ 0\\.008253937617039858\ \(0\)\
\-\ first\\:\\ 0\\.00821628491342651\ \(0\)\
\-\ by\\:\\ 0\\.008153987984211316\ \(0\)\
\-\ \\>\\:\\ 0\\.008135150471829698\ \(0\)\
\-\ disease\\:\\ 0\\.008004226597224665\ \(0\)\
\-\ should\\:\\ 0\\.007805755134351862\ \(0\)\
\-\ day\\:\\ 0\\.007773523866340772\ \(0\)\
\-\ between\\:\\ 0\\.007760732195484939\ \(0\)\
\-\ onset\\:\\ 0\\.00772900064735\ \(0\)\
\-\ any\\:\\ 0\\.007710129034591099\ \(0\)\
\-\ days\\:\\ 0\\.007504510877283603\ \(0\)\
\-\ tenderness\\:\\ 0\\.0074467401801766\ \(0\)\
\-\ month\\:\\ 0\\.007345600403440141\ \(0\)\
\-\ treated\\:\\ 0\\.007329085490211631\ \(0\)\
\-\ primary\\:\\ 0\\.0072532500369504194\ \(0\)\
\-\ infection\\:\\ 0\\.007117526000208616\ \(0\)\
\-\ his\\:\\ 0\\.007056988617899518\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0069977038234655745\ \(0\)\
\-\ axial\\:\\ 0\\.006987941192171551\ \(0\)\
\-\ abnormal\\:\\ 0\\.00698307232181923\ \(0\)\
\-\ weeks\\:\\ 0\\.006949219933814178\ \(0\)\
\-\ secondary\\:\\ 0\\.006845358070225809\ \(0\)\
\-\ shows\\:\\ 0\\.006731729798650082\ \(0\)\
\-\ and\\:\\ 0\\.00670520651724596\ \(0\)\
\-\ high\\:\\ 0\\.006700705046065374\ \(0\)\
\-\ are\\:\\ 0\\.006675494971516342\ \(0\)\
\-\ at\\:\\ 0\\.006634745861499329\ \(0\)\
\-\ \\:\\:\\ 0\\.006477219575877736\ \(0\)\
\-\ mild\\:\\ 0\\.006447717633040507\ \(0\)\
\-\ common\\:\\ 0\\.006407642441135808\ \(0\)\
\-\ patients\\:\\ 0\\.00633688996953016\ \(0\)\
\-\ symptoms\\:\\ 0\\.0061021704209115735\ \(0\)\
\-\ pain\\:\\ 0\\.005980562564646044\ \(0\)\
\-\ \\%\\:\\ 0\\.005711521585518646\ \(0\)\
\-\ small\\:\\ 0\\.005640616860690884\ \(0\)\
\-\ diagnosis\\:\\ 0\\.005622404959256217\ \(0\)\
\-\ can\\:\\ 0\\.005553645709080428\ \(0\)\
\-\ well\\:\\ 0\\.0055389139053543006\ \(0\)\
\-\ present\\:\\ 0\\.005530111042784186\ \(0\)\
\-\ this\\:\\ 0\\.00550794964649933\ \(0\)\
\-\ presents\\:\\ 0\\.005001846118933885\ \(0\)\
\-\ images\\:\\ 0\\.004697031209023937\ \(0\)\
\-\ male\\:\\ 0\\.0044275230311961985\ \(0\)\
\-\ \\(\\:\\ 0\\.004139608746383154\ \(0\)\
\-\ \\)\\:\\ 0\\.004089041215549026\ \(0\)\
\-\ the\\:\\ 0\\.003961297555977817\ \(0\)\
\-\ to\\:\\ 0\\.0036710725654124894\ \(0\)\
\-\ ct\\:\\ 0\\.0034249388349342205\ \(0\)\
\-\ a\\:\\ 0\\.003409167350876229\ \(0\)\
\-\ history\\:\\ 0\\.003381703546438634\ \(0\)\
\-\ of\\:\\ 0\\.00300439600911718\ \(0\)\
\-\ or\\:\\ 0\\.002869692690440423\ \(0\)\
\-\ was\\:\\ 0\\.0028317407513286153\ \(0\)\
\-\ no\\:\\ 0\\.0024654560192086017\ \(0\)\
\-\ patient\\:\\ 0\\.00245441814016157\ \(0\)\
\-\ in\\:\\ 0\\.0024148838403453003\ \(0\)\
\-\ with\\:\\ 0\\.002346788632175439\ \(0\)\
\-\ \\.\\:\\ 0\\.0021360752379492027\ \(0\)\
